vs
直觉外科（ISRG）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
直觉外科的季度营收约是Steris的1.9倍（$2.8B vs $1.5B），直觉外科净利率更高（29.8% vs 12.9%，领先16.9%），直觉外科同比增速更快（23.0% vs 9.2%），过去两年直觉外科的营收复合增速更高（17.4% vs 15.8%）
直觉外科（Intuitive Surgical）是美国医疗科技企业，主打研发、生产及销售微创外科手术机器人产品，核心产品为达芬奇手术系统，可有效提升患者临床治疗效果。该公司为纳斯达克100、标普100及标普500指数成分股，截至2021年末全球达芬奇系统装机量达6730台，其中美国市场占4139台。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
ISRG vs STE — 直观对比
营收规模更大
ISRG
是对方的1.9倍
$1.5B
营收增速更快
ISRG
高出13.8%
9.2%
净利率更高
ISRG
高出16.9%
12.9%
两年增速更快
ISRG
近两年复合增速
15.8%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $1.5B |
| 净利润 | $826.0M | $192.9M |
| 毛利率 | 66.1% | 43.8% |
| 营业利润率 | — | 18.3% |
| 净利率 | 29.8% | 12.9% |
| 营收同比 | 23.0% | 9.2% |
| 净利润同比 | 17.4% | 11.2% |
| 每股收益（稀释后） | $2.28 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISRGSTE
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.5B | $1.5B | ||
| Q2 25 | $2.4B | $1.4B | ||
| Q1 25 | $2.3B | $1.5B | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.0B | $1.3B |
净利润ISRGSTE
| Q1 26 | $826.0M | — | ||
| Q4 25 | $794.8M | $192.9M | ||
| Q3 25 | $704.4M | $191.9M | ||
| Q2 25 | $658.4M | $177.4M | ||
| Q1 25 | $698.4M | $145.7M | ||
| Q4 24 | $685.7M | $173.5M | ||
| Q3 24 | $565.1M | $150.0M | ||
| Q2 24 | $526.9M | $145.4M |
毛利率ISRGSTE
| Q1 26 | 66.1% | — | ||
| Q4 25 | 66.4% | 43.8% | ||
| Q3 25 | 66.4% | 44.2% | ||
| Q2 25 | 66.3% | 45.1% | ||
| Q1 25 | 64.7% | 43.3% | ||
| Q4 24 | 68.0% | 44.5% | ||
| Q3 24 | 67.4% | 43.6% | ||
| Q2 24 | 68.3% | 44.7% |
营业利润率ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | 30.2% | 18.3% | ||
| Q3 25 | 30.3% | 18.2% | ||
| Q2 25 | 30.5% | 17.7% | ||
| Q1 25 | 25.7% | 14.6% | ||
| Q4 24 | 30.4% | 17.9% | ||
| Q3 24 | 28.3% | 16.5% | ||
| Q2 24 | 28.2% | 14.5% |
净利率ISRGSTE
| Q1 26 | 29.8% | — | ||
| Q4 25 | 27.7% | 12.9% | ||
| Q3 25 | 28.1% | 13.1% | ||
| Q2 25 | 27.0% | 12.8% | ||
| Q1 25 | 31.0% | 9.8% | ||
| Q4 24 | 28.4% | 12.7% | ||
| Q3 24 | 27.7% | 11.3% | ||
| Q2 24 | 26.2% | 11.4% |
每股收益（稀释后）ISRGSTE
| Q1 26 | $2.28 | — | ||
| Q4 25 | $2.19 | $1.96 | ||
| Q3 25 | $1.95 | $1.94 | ||
| Q2 25 | $1.81 | $1.79 | ||
| Q1 25 | $1.92 | $1.48 | ||
| Q4 24 | $1.89 | $1.75 | ||
| Q3 24 | $1.56 | $1.51 | ||
| Q2 24 | $1.46 | $1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $17.6B | $7.2B |
| 总资产 | $20.1B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | $5.9B | $423.7M | ||
| Q3 25 | $4.9B | $319.2M | ||
| Q2 25 | $5.3B | $279.7M | ||
| Q1 25 | $4.5B | $171.7M | ||
| Q4 24 | $4.0B | $155.2M | ||
| Q3 24 | $4.2B | $172.2M | ||
| Q2 24 | $4.8B | $198.3M |
总债务ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益ISRGSTE
| Q1 26 | $17.6B | — | ||
| Q4 25 | $17.8B | $7.2B | ||
| Q3 25 | $16.9B | $7.0B | ||
| Q2 25 | $17.8B | $7.0B | ||
| Q1 25 | $17.1B | $6.6B | ||
| Q4 24 | $16.4B | $6.4B | ||
| Q3 24 | $15.6B | $6.6B | ||
| Q2 24 | $14.7B | $6.4B |
总资产ISRGSTE
| Q1 26 | $20.1B | — | ||
| Q4 25 | $20.5B | $10.6B | ||
| Q3 25 | $19.4B | $10.4B | ||
| Q2 25 | $20.2B | $10.4B | ||
| Q1 25 | $19.2B | $10.1B | ||
| Q4 24 | $18.7B | $10.0B | ||
| Q3 24 | $17.7B | $10.2B | ||
| Q2 24 | $16.6B | $10.1B |
负债/权益比ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $298.2M |
| 自由现金流经营现金流 - 资本支出 | — | $199.5M |
| 自由现金流率自由现金流/营收 | — | 13.3% |
| 资本支出强度资本支出/营收 | — | 6.6% |
| 现金转化率经营现金流/净利润 | — | 1.55× |
| 过去12个月自由现金流最近4个季度 | — | $917.1M |
8季度趋势，按日历期对齐
经营现金流ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | $892.5M | $298.2M | ||
| Q3 25 | $841.0M | $287.8M | ||
| Q2 25 | $715.4M | $420.0M | ||
| Q1 25 | $581.6M | $260.8M | ||
| Q4 24 | $822.6M | $332.8M | ||
| Q3 24 | $706.5M | $250.7M | ||
| Q2 24 | $620.5M | $303.7M |
自由现金流ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | $730.0M | $199.5M | ||
| Q3 25 | $735.6M | $201.3M | ||
| Q2 25 | $560.1M | $326.4M | ||
| Q1 25 | $465.0M | $189.9M | ||
| Q4 24 | $510.6M | $243.6M | ||
| Q3 24 | $458.6M | $148.8M | ||
| Q2 24 | $311.1M | $195.7M |
自由现金流率ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | 25.5% | 13.3% | ||
| Q3 25 | 29.4% | 13.8% | ||
| Q2 25 | 23.0% | 23.5% | ||
| Q1 25 | 20.6% | 12.8% | ||
| Q4 24 | 21.2% | 17.8% | ||
| Q3 24 | 22.5% | 11.2% | ||
| Q2 24 | 15.5% | 15.3% |
资本支出强度ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 6.6% | ||
| Q3 25 | 4.2% | 5.9% | ||
| Q2 25 | 6.4% | 6.7% | ||
| Q1 25 | 5.2% | 4.8% | ||
| Q4 24 | 12.9% | 6.5% | ||
| Q3 24 | 12.2% | 7.7% | ||
| Q2 24 | 15.4% | 8.4% |
现金转化率ISRGSTE
| Q1 26 | — | — | ||
| Q4 25 | 1.12× | 1.55× | ||
| Q3 25 | 1.19× | 1.50× | ||
| Q2 25 | 1.09× | 2.37× | ||
| Q1 25 | 0.83× | 1.79× | ||
| Q4 24 | 1.20× | 1.92× | ||
| Q3 24 | 1.25× | 1.67× | ||
| Q2 24 | 1.18× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISRG
| Instruments and accessories | $1.7B | 61% |
| Systems | $650.7M | 23% |
| Services | $433.7M | 16% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
